GANX insider transaction filings

Gain Therapeutics, Inc. — 34 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-17. Screen GANX transaction legs live →

Insider transaction summary — last 90 days

2026-06-24 to 2026-09-22, from the filings listed below: 6 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By insider — same window

Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

InsiderFilingsPurchases (P)Sales (S)Other legs
GOLDSTEIN DOV A MD — Director11
HASLER HANS PETER — Director11
Islam Khalid — Director11
Melincoff Gwen A — Director11
Nicaise Claude — Director11
Riley Jeffrey Scott — Director11

Recent Form 4 filings — Gain Therapeutics, Inc.

FiledFormInsiderReported transactionsSource
2026-07-174Islam Khalid — DirectorGrant/award (A): 25,000 (derivative) @ $0EDGAR
2026-07-174Nicaise Claude — DirectorGrant/award (A): 25,000 (derivative) @ $0EDGAR
2026-07-174Melincoff Gwen A — DirectorGrant/award (A): 25,000 (derivative) @ $0EDGAR
2026-07-174Riley Jeffrey Scott — DirectorGrant/award (A): 25,000 (derivative) @ $0EDGAR
2026-07-174HASLER HANS PETER — DirectorGrant/award (A): 25,000 (derivative) @ $0EDGAR
2026-07-174GOLDSTEIN DOV A MD — DirectorGrant/award (A): 25,000 (derivative) @ $0EDGAR
2026-03-264Fuggetta Gianluca — See RemarkGrant/award (A): 50,000 (derivative) @ $0EDGAR
2026-03-264Mack Gene — CEO, President, DirectorGrant/award (A): 200,000 (derivative) @ $0EDGAR
2025-06-254Islam Khalid — DirectorGrant/award (A): 15,000 (derivative) @ $0EDGAR
2025-06-254Nicaise Claude — DirectorGrant/award (A): 15,000 (derivative) @ $0EDGAR
2025-06-254Melincoff Gwen A — DirectorGrant/award (A): 15,000 (derivative) @ $0EDGAR
2025-06-254Riley Jeffrey Scott — DirectorGrant/award (A): 15,000 (derivative) @ $0EDGAR
2025-06-254RICHMAN ERIC I — DirectorGrant/award (A): 15,000 (derivative) @ $0EDGAR
2025-06-254HASLER HANS PETER — DirectorGrant/award (A): 15,000 (derivative) @ $0EDGAR
2025-06-254GOLDSTEIN DOV A MD — DirectorGrant/award (A): 15,000 (derivative) @ $0EDGAR
2025-03-214Fuggetta Gianluca — See RemarkGrant/award (A): 50,000 (derivative) @ $0EDGAR
2025-03-214Mack Gene — CEO, President, DirectorGrant/award (A): 200,000 (derivative) @ $0EDGAR
2025-01-074Mack Gene — CEO, President, DirectorGrant/award (A): 271,325 (derivative) @ $0EDGAR
2024-08-124Mack Gene — CFO and Interim CEOPurchase (P): 14,400 @ $1.01EDGAR
2024-08-124Islam Khalid — Executive Chairman, DirectorPurchase (P): 50,000 @ $1.00EDGAR
2024-07-014RICHMAN ERIC I — DirectorPurchase (P): 5,000 @ $1.23 · Purchase (P): 12,000 @ $1.21EDGAR
2024-06-264Islam Khalid — DirectorGrant/award (A): 15,000 (derivative) @ $0EDGAR
2024-06-264Nicaise Claude — DirectorGrant/award (A): 15,000 (derivative) @ $0EDGAR
2024-06-264Melincoff Gwen A — DirectorGrant/award (A): 15,000 (derivative) @ $0EDGAR
2024-06-264Riley Jeffrey Scott — DirectorGrant/award (A): 15,000 (derivative) @ $0EDGAR
2024-06-264RICHMAN ERIC I — DirectorGrant/award (A): 15,000 (derivative) @ $0EDGAR
2024-06-264HASLER HANS PETER — DirectorGrant/award (A): 15,000 (derivative) @ $0EDGAR
2024-06-264GOLDSTEIN DOV A MD — DirectorGrant/award (A): 15,000 (derivative) @ $0EDGAR
2024-04-084Mack Gene — Chief Financial OfficerGrant/award (A): 200,000 (derivative) @ $0EDGAR
2024-04-014Riley Jeffrey Scott — DirectorPurchase (P): 30,000 @ $3.86EDGAR
2024-03-284Alder Matthias — Chief Executive Officer, DirectorOption exercise (M): 18,750 · Option exercise (M): 825 · Option exercise (M): 637 · Tax withholding (F): 6,085 @ $4.06 · Option exercise (M): 18,750 (derivative) @ $0 · Option exercise (M): 825 (derivative) @ $0 · +1 moreEDGAR
2024-03-254Fuggetta Gianluca — See RemarkGrant/award (A): 50,000 (derivative) @ $0EDGAR
2024-03-254Alder Matthias — Chief Executive Officer, DirectorGrant/award (A): 370,000 (derivative) @ $0EDGAR
2023-12-224Alder Matthias — Chief Executive Officer, DirectorOption exercise (M): 637 · Sale (S): 206 @ $2.46 · Option exercise (M): 637 (derivative) @ $0EDGAR

Recent 8-K events — Gain Therapeutics, Inc.

FiledFormItems reportedSource
2026-08-118-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-168-K8.01 — Other EventsEDGAR
2026-06-298-K8.01 — Other EventsEDGAR
2026-06-258-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2026-05-268-K8.01 — Other EventsEDGAR
2026-05-118-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-03-268-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-03-188-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-02-038-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2025-12-188-K8.01 — Other EventsEDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=GANX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →